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Abstract: Recent studies have investigated the relationship between sarcopenia and non-alcoholic
fatty liver disease (NAFLD); however, there is no unified definition of sarcopenia. Thus, we aimed to
investigate the differences among three skeletal muscle mass indices (SMI) in predicting NAFLD.
This study included 8133 adults from the 2008–2010 Korea National Health and Nutrition Survey.
SMI was calculated as appendicular skeletal muscle mass divided by height-square (hSMI), weight
(wSMI), or body mass index (bSMI). The presence of NAFLD was defined by using the NAFLD-liver
fat score. On the receiver operating characteristic curve analysis, the predictive power of wSMI for
NAFLD was significantly higher than those of hSMI and bSMI in men (wSMI vs. hSMI, p = 0.003;
wSMI vs. bSMI, p < 0.001). In women, the predictive power of hSMI was only significantly higher
than that of bSMI (p = 0.023), and other predictive powers were not significantly different. In addition,
hSMI was correlated with insulin resistance and NAFLD-liver fat score in the opposite direction to
wSMI and bSMI in both men and women. Among the three definitions of SMI, wSMI showed the
highest diagnostic performance for predicting NAFLD in men, suggesting the importance of defining
sarcopenia for its association with specific diseases.
Keywords: non-alcoholic fatty liver; muscle mass; skeletal muscle index; sarcopenia; insulin resistance
1. Introduction
Sarcopenia is a common skeletal muscle disorder, characterized by low muscle
strength, low muscle quantity, and low physical performance [1]. Sarcopenia was first
described as a decrease in muscle mass associated with normal aging [2]; however, it has
become a serious medical problem since it is known to be associated with not only frailty,
poor quality of life, and disability in the elderly [3], but also cardio-metabolic disorders [4].
The close link between sarcopenia and cardio-metabolic disorders including type 2 diabetes
and cardiovascular disease has been explained by the multifactorial etiology of sarcopenia,
including chronic inflammation, insulin resistance, and endocrine abnormalities [5].
Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease
worldwide. The global prevalence of NAFLD was reported to be about 25% in 2018 [6],
which increased accompanied by the increasing prevalence of obesity and insulin resis-
tance [7–9]. As the Westernized lifestyle and the rate of receiving health screenings have
increased, the recent prevalence of NAFLD in Korea has also increased. The prevalence
of NAFLD is estimated to be over 30% in Korea [10]. NAFLD ranges from simple liver
steatosis to steatohepatitis, and it can progress to liver cirrhosis and liver failure [11]. The
pathophysiology of NAFLD is complex, and is determined by numerous mechanisms
including genetic, environmental, and metabolic factors [12]. Therefore, there has been
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increased interest in identifying the risk factors for NAFLD and its progression to compli-
cations [11,13].
Recent studies have investigated the relationship between sarcopenia and NAFLD
because of their common pathophysiological causes such as systemic inflammation and
insulin resistance [14–16]. However, the findings are still inconsistent, and it is also unclear
whether a shortage of muscle mass, a relative excess of fat mass, or both, are associated
with NAFLD.
Thus, we aimed to investigate which of the three different skeletal muscle mass indices
(adjusting for height, weight, or body mass index) could predict NAFLD most accurately.
Furthermore, we examined the correlations between the three skeletal muscle mass indices
and both insulin resistance and NAFLD to characterize the link between sarcopenia and
NAFLD via insulin resistance.
2. Materials and Methods
2.1. Study Population
We analyzed all data from the 2008–2010 Korean National Health and Nutrition
Examination Survey (KNHANES). The KNHANES, annually conducted by the Korea
Centers for Disease Control and Prevention (KCDC), is a nationwide, representative,
and population-based survey. This survey monitors the health and nutritional status
of the Korean population [17]. To represent the Korean population, participants were
selected by using the proportional allocation-systematic sampling method with multistage
stratification based on sex, age, and geographic area. Sampling weights were assigned
to each participant to generalize the units for representing the Korean population [18].
Detailed information about the KNHANES is available through the KNHANES website
(http://knhanes.cdc.go.kr, accessed on 7 June 2021).
A total of 29,235 people participated in the 2008–2010 KNHANES. We excluded
7424 participants under 19 years of age. Among the remaining 21,811 adults over 19 years
old, we further excluded heavy alcoholics (n = 1673) and participants with positive hepatitis
B surface antigen (n = 652); chronic hepatitis C viral infection (n = 11); insufficient data
to evaluate NAFLD liver-fat score (n = 9143); missing whole-body dual-energy X-ray
absorptiometry (DEXA) data (n = 1921); or missing height or weight measurement data
(n = 8). Finally, a total of 8133 participants (3277 men and 4906 women) were included in
the analysis (Figure 1). There were no pregnant or lactating women in the final analysis.
2.2. Assessment of NAFLD
NAFLD was defined by using a validated surrogate index, the NAFLD-liver fat
score [19]. The calculation equation is as follows: −2.89 + 1.18 × metabolic syndrome
(yes = 1/no = 0) + 0.45 × diabetes mellitus (yes = 2/no = 0) + 0.15 × fasting insulin
(µU/mL) + 0.04 × aspartate aminotransferase (AST, U/L) + 0.94 × AST/alanine amino-
transferase (ALT, U/L) ratio.
2.3. Assessment Body Composition
Height (m) and weight (kg) were measured to the nearest 0.1 cm and 0.1 kg, respec-
tively. Body mass index (BMI) was calculated as the weight divided by height squared
(kg/m2). A BMI less than 18.5 kg/m2 was considered underweight, and a BMI over
25 kg/m2 was considered obese according to the definition of the Korean Society for the
Study of Obesity [20]. Waist circumference (cm) was measured in the horizontal plane
midway between the iliac crest and the lowest rib.
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Figure 1. Flowchart of the study population selection.
During the 2008–2010 KNHANES, body composition data were collected from the
head, arms, legs, trunk, pelvic region, and whole body by using whole-body DEXA (QDR
4500 A; Hologic Inc., Bedford, MA, USA). For each anatomical region, bone mineral content
(g), bone mineral density (g/cm2), fat mass (g), lean body mass (g), and total fat percentage
(fat mass/total mass × 100) were recorded. We calculated skeletal muscle mass as lean
body mass (g)—bone mineral content (g). Appendicular skeletal muscle mass (ASM) was
calculated by summation of skeletal muscle mass from both arms and legs. Subtotal skeletal
muscle mass was calculated by summation of skeletal muscle mass from the whole body
except for the head area.
2.4. Three Different Definitions of Skeletal Muscle Mass Index
Skeletal muscle mass index (SMI) and low skeletal muscle mass index (LSMI) were
defined in three different ways. First, height square-adjusted SMI (hSMI) was ASM/height2
(kg/m2), and height square-adjusted LSMI (hLSMI) was defined as hSMI of <7.0 kg/m2
for men and <5.4 kg/m2 for women based on the Asian Working Group for Sarcopenia
criteria [21]. Second, weight-adjusted SMI (wSMI) was ASM/weight × 100 (%), and
weight-adjusted LSMI (wLSMI) was defined as wSMI values below −2 standard deviations
of the sex-specific mean values of referent young adults aged 19–29 years [22]. Third,
BMI-adjusted SMI (bSMI) was ASM/BMI (m2), and BMI-adjusted LSMI (bLSMI) was
defined as bSMI <0.789 for men and <0.512 for women based on the Foundation for the
National Institutes of Health (FNIH) Sarcopenia Project criteria [23].
2.5. Data Collection
Blood pressure was measured in a sitting position after at least 30 min of resting. Mean
blood pressure (MBP; mmHg) was calculated using the following formula: MBP = [systolic
blood pressure (SBP) + 2 × diastolic blood pressure (DBP)]/3. We defined heavy alcohol
drinkers as adults who drink ≥30 g/day alcohol among men and ≥20 g/day alcohol among
women. Smoking status was divided into two categories: current smoker or not. Based on
the International Physical Activity Questionnaire, we defined regular exercise as ≥20 min
of vigorous exercise for ≥3 days/week, or ≥30 min of moderate exercise/walking for
≥5 days/week. Each participant’s blood sample was collected from the antecubital vein af-
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ter at least 8 h of fasting. Using a Hitachi 7600 Analyzer (Hitachi Co., Tokyo, Japan), plasma
glucose, serum insulin, total cholesterol, triglyceride, high-density lipoprotein (HDL)
cholesterol, AST and ALT levels were measured. The homeostatic assessment model of
insulin resistance (HOMA-IR) was calculated following the equation: HOMA-IR = plasma
glucose (mg/dL) × serum insulin (µU/mL)/405. A 24-h dietary recall method was used
to assess participant’s diets. Total calorie intake (kcal/day) and percentage of protein,
carbohydrates, and fat intake to total caloric intake (%) were calculated. Metabolic syn-
drome was defined as three or more of the following five criteria being met [24]: (1) waist
circumference ≥90 cm in men or ≥85 cm in women, according to the Korean-specific
cut-offs for abdominal obesity of the Korean Society of Obesity [25]; (2) SBP ≥130 mmHg,
DBP ≥85 mmHg, or treatment with anti-hypertensive medications; (3) fasting plasma
glucose level ≥100 mg/dL, glycosylated hemoglobin (HbA1c) ≥ 6.5%, or treatment with
anti-diabetic medications; (4) serum triglyceride level ≥150 mg/dL; (5) serum HDL choles-
terol level <40 mg/dL in men or <50 mg/dL in women. Based on American Diabetes
Association criteria [26], diabetes mellitus was defined as either of the following: (1) fasting
plasma glucose level ≥126 mg/dL, (2) HbA1c ≥ 6.5%, or treatment with anti-diabetic
medications. Chronic diseases included the following six comorbid conditions: diabetes
mellitus, myocardial infarction, stroke, chronic obstructive lung disease, chronic kidney
disease stages from 3 to 5, and any history of cancer, considering the components of the
Charlson comorbidity index [27]. Participants were categorized into three groups based on
these comorbidities: zero, one, or at least two chronic diseases.
2.6. Statistical Analysis
We applied sampling weights to the participants to derive data representative of
the Korean population. The weights were adjusted with the values for the inverse of the
response rates and the inverse of the selection probability to the sex- and age-specific values
for the Korean population (post-stratification) [17]. All data analyzed in this study are
presented as a mean ± standard error (SE) or percentage (SE). To compare differences of
continuous variables between participants with or without NAFLD, weighted generalized
linear regression analysis was used. Weighted chi-square tests were used for categorical
variables. Weighted logistic regression analysis was served to calculate odds ratio (OR)
with 95% confidence interval (CI) for NAFLD according to different definitions of LSMI.
We adjusted for age in Model 1. We adjusted for age and lifestyle (smoking status, alcohol
drinking status, and regular exercise) in Model 2. We additionally adjusted for mean
blood pressure, plasma glucose, serum total cholesterol, serum ALT, serum vitamin D
levels and number of chronic diseases in Model 3. The receiver operating characteristics
(ROC) curves were used to compare the discriminative power of wSMI, hSMI, and bSMI
to predict NAFLD using the areas under the ROC curves (AUC). In addition, weighted
Pearson’s correlation tests were performed to calculate correlation coefficients (r) between
wSMI/hSMI/bSMI and both HOMA-IR and NAFLD-liver fat score. Steiger’s Z tests were
used to compare r values of hSMI and bSMI with that of wSMI. All statistical analyses were
conducted using SPSS statistical software (version 25.0; SPSS Inc., Chicago, IL, USA) and R
(Version 4.0.3; R Foundation for Statistical Computing, Vienna, Austria). A p value of <0.05
was considered statistically significant.
3. Results
3.1. Clinical Characteristics of the Study Population
Table 1 represents the clinical characteristics of the study population. Participants
with NAFLD showed significantly higher weight, BMI, waist circumference, MBP, plasma
glucose, insulin, HOMA-IR, serum total cholesterol, AST and ALT levels, and lower
proportion without chronic disease than participants without NAFLD in both men and
women. In women only, the average age, percentage of carbohydrate intake, and percentage
of fat intake were significantly higher, and height, the proportion of alcohol drinkers and
those who exercise regularly were significantly lower in participants with NAFLD. Only in
Life 2021, 11, 751 5 of 11
men, the proportion of never smokers was significantly lower in participants with NAFLD.
In both men and women, NAFLD-liver fat score, ASM, and hSMI were significantly
higher in people with NAFLD, whereas wSMI and bSMI were significantly lower in those
with NAFLD.
Table 1. Clinical characteristics of the study population.
Men Women
Variables WithoutNAFLD With NAFLD p
Without
NAFLD With NAFLD p
Unweighted
number, n 2311 916 3920 986
Age, years 48.6 ± 0.5 47.3 ± 0.8 0.153 46.6 ± 0.4 54.5 ± 0.7 <0.001
Height, m 1.698 ± 0.002 1.702 ± 0.004 0.356 1.572 ± 0.002 1.555 ± 0.003 <0.001
Weight, kg 67.4 ± 0.3 74.4 ± 0.6 <0.001 56.1 ± 0.2 62.0 ± 0.5 <0.001
BMI, kg/m2 23.3 ± 0.1 25.6 ± 0.2 <0.001 22.7 ± 0.1 25.6 ± 0.2 <0.001
Waist
circumference, cm 82.3 ± 0.3 88.8 ± 0.4 <0.001 76.3 ± 0.3 85.2 ± 0.5 <0.001
Mean blood
pressure, mmHg 93.2 ± 0.3 95.4 ± 0.5 0.001 87.5 ± 0.4 93.6 ± 0.6 <0.001
Smoking status, %
(SE) 0.030 0.134
Never smoker 21.7 (1.1) 17.2 (1.6) 90.0 (0.7) 92.0 (1.3)
Ex-smoker 13.9 (1.2) 17.9 (2.0) 1.4 (0.3) 0.7 (0.2)
Current smoker 64.4 (1.5) 64.9 (2.3) 8.6 (0.6) 7.3 (1.3)
Alcohol drinker, %
(SE) 73.1 (1.4) 69.7 (2.1) 0.151 39.8 (1.1) 34.4 (2.1) 0.033
Regular exercise,
% (SE) 27.6 (1.4) 24.5 (1.7) 0.145 21.2 (1.0) 16.9 (1.8) <0.001
Glucose, mg/dL 95.7 ± 0.4 108.3 ± 1.2 <0.001 92.5 ± 0.3 110.0 ± 1.3 <0.001
Insulin, µIU/mLt 8.3 ± 0.1 13.7 ± 0.3 <0.001 8.7 ± 0.1 14.4 ± 0.3 <0.001
HOMA-IR 2.0 ± 0.0 3.7 ± 0.1 <0.001 2.0 ± 0.0 3.9 ± 0.1 <0.001
Total cholesterol,
mg/dL 186.1 ± 0.9 191.5 ± 1.7 0.006 185.5 ± 0.8 196.0 ± 1.7 <0.001
AST, U/L 21.5 ± 0.2 32.7 ± 1.4 <0.001 18.7 ± 0.1 26.8 ± 0.7 <0.001
ALT, U/L 20.8 ± 0.3 42.9 ± 1.3 <0.001 14.9 ± 0.1 29.1 ± 0.9 <0.001
Total caloric
intake, kcal/day 2228.9 ± 28.6 2222.2 ± 39.7 0.879 1653.8 ± 14.8 1595.7 ± 33.3 0.096
Protein intake, % 14.5 ± 0.1 14.7 ± 0.2 0.458 14.2 ± 0.1 14.1 ± 0.2 0.441
Carbohydrate
intake, % 65.3 ± 0.4 64.9 ± 0.7 0.562 69.5 ± 0.3 71.2 ± 0.6 0.005
Fat intake, % 17.2 ± 0.3 17.7 ± 0.5 0.301 16.7 ± 0.2 15.6 ± 0.4 0.028
Number of chronic
diseases, % (SE) <0.001 <0.001
0 86.34 (1.0) 64.7 (2.2 89.8 (0.7) 60.0 (2.3)
1 10.7 (0.9) 27.6 (2.1) 9.0 (0.7) 32.4 (2.2)




0.018 0.465 ± 0.056 <0.001
−1.915 ±
0.015 0.257 ± 0.039 <0.001
ASM, kg 21.9 ± 0.1 23.0 ± 0.2 <0.001 14.3 ± 0.1 15.0 ± 0.1 <0.001
wSMI, % 32.6 ± 0.1 31.0 ± 0.1 <0.001 25.5 ± 0.1 24.3 ± 0.1 <0.001
hSMI, kg/m2 7.6 ± 0.0 7.9 ± 0.1 <0.001 5.8 ± 0.0 6.2 ± 0.0 <0.001
bSMI, m2 0.944 ± 0.004 0.902 ± 0.006 <0.001 0.640 ± 0.003 0.590 ± 0.004 <0.001
p values were derived from weighted generalized linear regression analysis for continuous variables and weighted
chi-square tests for categorical variables. Abbreviations: NAFLD, non-alcoholic fatty liver disease; BMI, body
mass index; HOMA-IR, homeostatic model assessment of insulin resistance; AST, aspartate aminotransferase;
ALT, alanine aminotransferase; ASM, appendicular skeletal muscle mass; wSMI, weight-adjusted skeletal muscle
mass index; hSMI, height-adjusted skeletal muscle mass index; bSMI, body mass index-adjusted skeletal muscle
mass index; SE, standard error.
3.2. Comparison of Body Composition according to Three Different Definitions of LSMI
Table 2 shows body composition according to three different definitions of LSMI.
The mean values of ASM and subtotal skeletal muscle mass were significantly lower, and
percentage of appendicular fat was significantly higher in participants with sarcopenia in
all three definitions. However, appendicular fat mass, subtotal fat mass, and percentage
of subtotal fat mass were significantly higher in sarcopenia defined by wSMI and bSMI,
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whereas appendicular fat mass and subtotal fat mass were lower in sarcopenia defined by
hSMI, in both men and women.
Table 2. Body composition according to three different definitions of LSMI.
LSMI Defined by wSMI LSMI Defined by hSMI LSMI Defined by bSMI
No Yes p No Yes p No Yes p
Men
Unweighted number, n 3106 121 2463 764 2851 376
Appendicular skeletal
muscle mass, kg 22.3 ± 0.1 19.1 ± 0.4 <0.001 23.3 ± 0.1 18.5 ± 0.1 <0.001 22.6 ± 0.1 18.5 ± 0.2 <0.001
Appendicular fat mass,
kg 5.9 ± 0.0 8.9 ± 0.2 <0.001 6.2 ± 0.0 5.2 ± 0.1 <0.001 5.9 ± 0.0 6.7 ± 0.2 <0.001
Percentage of
appendicular fat, % 19.6 ± 0.2 30.3 ± 0.5 <0.001 19.8 ± 0.2 20.7 ± 0.4 0.020 19.4 ± 0.2 25.0 ± 0.4 <0.001
Subtotal skeletal muscle
mass, kg * 46.9 ± 0.2 42.9 ± 1.0 <0.001 48.7 ± 0.2 39.8 ± 0.2 <0.001 47.4 ± 0.2 40.9 ± 0.4 <0.001
Subtotal fat mass, kg 14.2 ± 0.1 22.8 ± 0.6 <0.001 15.1 ± 0.2 12.5 ± 0.3 <0.001 14.2 ± 0.2 17.4 ± 0.4 <0.001
Percentage of subtotal
fat, % 22.1 ± 0.2 33.6 ± 0.4 <0.001 22.5 ± 0.2 22.6 ± 0.4 0.667 21.8 ± 0.2 28.6 ± 0.4 <0.001
Women
Unweighted number, n 4677 229 3518 1388 4397 509
Appendicular skeletal
muscle mass, kg 14.5 ± 0.0 12.6 ± 0.3 <0.001 15.1 ± 0.0 12.5 ± 0.1 <0.001 14.6 ± 0.0 12.3 ± 0.1 <0.001
Appendicular fat mass,
kg 8.4 ± 0.0 11.4 ± 0.3 <0.001 8.8 ± 0.0 7.9 ± 0.0 <0.001 8.5 ± 0.0 9.4 ± 0.2 <0.001
Percentage of
appendicular fat, % 35.2 ± 0.1 45.4 ± 0.8 <0.001 35.2 ± 0.1 36.8 ± 0.3 <0.001 35.0 ± 0.1 41.3 ± 0.6 <0.001
Subtotal skeletal muscle
mass, kg * 32.5 ± 0.1 30.4 ± 0.6 0.001 33.8 ± 0.1 28.8 ± 0.1 <0.001 32.8 ± 0.1 29.4 ± 0.3 <0.001
Subtotal fat mass, kg 17.8 ± 0.1 26.2 ± 0.5 <0.001 19.1 ± 0.1 15.8 ± 0.2 <0.001 17.8 ± 0.1 22.0 ± 0.4 <0.001
Percentage of subtotal
fat, % 34.0 ± 0.1 45.0 ± 0.6 <0.001 34.7 ± 0.2 34.0 ± 0.3 0.044 33.8 ± 0.1 41.5 ± 0.5 <0.001
wSMI was defined as appendicular skeletal muscle mass divided by weight (%); hSMI index was defined as appendicular skeletal muscle
mass divided by height square (kg/m2); bSMI was defined as appendicular skeletal muscle mass divided by body mass index (m2).
* subtotal area includes whole body except the head area. Abbreviations: LSMI, low skeletal muscle mass index; wSMI, weight-adjusted
skeletal muscle mass index; hSMI, height-adjusted skeletal muscle mass index; bSMI, body mass index-adjusted skeletal muscle mass index.
3.3. Relationship between Three Different Definitions of LSMI and NAFLD
Table 3 represents the results of weighted logistic regression analysis showing the
relationship between three different definitions of LSMI and NAFLD. The unadjusted ORs
(95% CI) for NAFLD of wLSMI/hLSMI/bLSMI were 3.39 (1.92–5.97), 0.55 (0.41–0.74) and
1.88 (1.36–2.59) in men and 2.37 (1.62–3.48), 0.38 (0.29–0.50) and 2.12 (1.59–2.84) in women,
respectively. After adjusting for age, smoking status, alcohol drinking status, regular
exercise, mean blood pressure, serum total cholesterol, serum vitamin D levels, number of
chronic diseases, and percentage of protein intake, the adjusted ORs (95% CI) for NAFLD
of wLSMI/hLSMI/bLSMI were 2.52 (1.20–5.30), 0.50 (0.36–0.71), and 1.55 (1.03–2.33) in
men and 1.98 (1.34–2.93), 0.48 (0.35–0.65), and 1.30 (0.92–1.85) in women, respectively.
3.4. Comparison of the Predictive Power of Three Different Definitions of SMI for NAFLD
Figure 2 compares the predictive power of wSMI, hSMI, and bSMI for NAFLD. The
AUC of wSMI, hSMI, and bSMI were 0.657, 0.604, and 0.596 in men and 0.634, 0.661, and
0.626 in women, respectively. In men, despite the relatively low AUC, we found that the
predictive power was highest in wSMI, followed by hSMI and bSMI (wSMI vs. hSMI,
p = 0.003; wSMI vs. bSMI, p < 0.001). There was no significant difference in the predictive
power between hSMI and bSMI (p = 0.645). In women, the predictive power of hSMI was
significantly higher than that of bSMI (hSMI vs. bSMI, p = 0.023); however, there were
no differences in the predictive power between wSMI and hSMI, bSMI (wSMI vs. hSMI,
p = 0.075; wSMI vs. bSMI, p = 0.183).
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No Yes No Yes
OR (95% CI) p OR (95% CI) p
LSMI defined by wSMI
Unadjusted 1 (Ref.) 3.39 (1.92–5.97) <0.001 1 (Ref.) 2.37 (1.62–3.48) <0.001
Model 1 1 (Ref.) 3.67 (2.08–6.47) <0.001 1 (Ref.) 1.83 (1.27–2.62) 0.001
Model 2 1 (Ref.) 3.61(2.09–6.26) <0.001 1 (Ref.) 1.82 (1.27–2.63) 0.001
Model 3 1 (Ref.) 2.52 (1.20–5.30) 0.015 1 (Ref.) 1.98 (1.34–2.93) 0.001
LSMI defined by hSMI
Unadjusted 1 (Ref.) 0.55 (0.41–0.74) <0.001 1 (Ref.) 0.38 (0.29–0.50) <0.001
Model 1 1 (Ref.) 0.56 (0.42–0.75) <0.001 1 (Ref.) 0.44 (0.34–0.57) <0.001
Model 2 1 (Ref.) 0.55 (0.41–0.74) <0.001 1 (Ref.) 0.43 (0.33–0.56) <0.001
Model 3 1 (Ref.) 0.50 (0.36–0.71) <0.001 1 (Ref.) 0.48 (0.35–0.65) <0.001
LSMI defined by bSMI
Unadjusted 1 (Ref.) 1.88 (1.36–2.59) <0.001 1 (Ref.) 2.12 (1.59–2.84) <0.001
Model 1 1 (Ref.) 2.15 (1.53–3.02) <0.001 1 (Ref.) 1.35 (0.99–1.84) 0.056
Model 2 1 (Ref.) 2.06 (1.46–2.90) <0.001 1 (Ref.) 1.36 (1.00–1.85) 0.054
Model 3 1 (Ref.) 1.55 (1.03–2.33) 0.001 1 (Ref.) 1.30 (0.92–1.85) 0.141
Model 1: Adjusted for age; Model 2: Adjusted for age, smoking status, alcohol drinking status, and regular exercise; Model 3: Adjusted
for age, smoking status, alcohol drinking status, regular exercise, mean blood pressure, serum total cholesterol, serum vitamin D levels,
number of chronic diseases, and percentage of protein intake. Abbreviations: LSMI, low skeletal muscle mass index; wSMI, weight-adjusted
skeletal muscle mass index; hSMI, height-adjusted skeletal muscle mass index; bSMI, body mass index-adjusted skeletal muscle mass
index; NAFLD, non-alcoholic fatty liver disease; OR, odds ratio; CI, confidence interval.
Figure 2. Comparison of the predictive power of three different definitions of SMI for NAFLD in (a) men and (b) women.
3.5. Correlations between Three Different Definitions of SMI and HOMA-IR/NAFLD
Table 4 shows a comparison of r values between three definitions of SMI and HOMA-
IR. The r values between wSMI/hSMI/bSMI and HOMA-IR were −0.318, 0.192, and
−0.212 in men and −0.214, 0.290, and −0.184 in women, respectively. In men, the absolute
value of r of wSMI was significantly higher than that of hSMI or bSMI (wSMI vs. hSMI,
p value < 0.001; wSMI vs. bSMI, p < 0.001). In women, the absolute value of r of wSMI was
significantly lower than that of hSMI (p < 0.001) and higher than that of bSMI (p < 0.001).
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Table 4. Comparison of correlation coefficients (r) between three different definitions of SMI and
HOMA-IR.
r p * p **
Men
wSMI −0.318 <0.001 Ref.
hSMI 0.192 <0.001 <0.001
bSMI −0.212 <0.001 <0.001
Women
wSMI −0.214 <0.001 Ref.
hSMI 0.290 <0.001 <0.001
bSMI −0.184 <0.001 <0.001
* p for r between wSMI/hSMI/bSMI and HOMA-IR. ** p indicates p values for comparison of absolute values of r
using Steiger’s Z-test. Abbreviations: wSMI, weight-adjusted skeletal muscle mass index; hSMI, height-adjusted
skeletal muscle mass index; bSMI, body mass index-adjusted skeletal muscle mass index; HOMA-IR, homeostatic
model assessment of insulin resistance.
Table 5 shows a comparison of r values between three definitions of SMI and NAFLD-
liver fat score; r values between wSMI/hSMI/bSMI and NAFLD-liver fat score were
−0.283, 0.224, and −0.182 in men and −0.237, 0.302, and −0.232 in women, respectively. In
men, the absolute value of r of wSMI was significantly higher than those of hSMI or bSMI
(wSMI vs. hSMI, p = 0.004; wSMI vs. bSMI, p < 0.001). In women, the absolute value of r of
wSMI was significantly lower than that of hSMI (wSMI vs. hSMI, p < 0.001), whereas there
was no significant difference between the absolute value of r of wSMI and bSMI (wSMI vs.
bSMI, p = 0.542).
Table 5. Comparison of correlation coefficients (r) between three different definitions of SMI and
NAFLD-liver fat score.
r p * p **
Men
wSMI −0.283 <0.001 Ref
hSMI 0.224 <0.001 0.004
bSMI −0.182 <0.001 <0.001
Women
wSMI −0.237 <0.001 Ref
hSMI 0.302 <0.001 <0.001
bSMI −0.232 <0.001 0.542
* p for r between wSMI/hSMI/bSMI and NAFLD-liver fat score. ** p indicates p values for comparison of absolute
values of r using Steiger’s Z-test. Abbreviations: wSMI, weight-adjusted skeletal muscle mass index; hSMI,
height-adjusted skeletal muscle mass index; bSMI, body mass index-adjusted skeletal muscle mass index; NAFLD,
non-alcoholic fatty liver disease.
4. Discussion
We examined the predictive power of three different definitions of skeletal muscle
mass indices for NAFLD in a representative sample of Korean adults. Our results show
that the predictive power of wSMI was significantly higher than those of hSMI and bSMI
in men. The predictive power of hSMI was only significantly higher than that of bSMI in
women; however, there were no significant differences between wSMI and hSMI or bSMI
in women. In addition, wSMI and bSMI were negatively correlated with HOMA-IR and
NAFLD-liver fat score, whereas hSMI was positively correlated in both men and women.
Many expert groups have suggested operational criteria for sarcopenia using the
different anthropometric indices (e.g., weight-adjusted, height square-adjusted, and BMI-
adjusted indices) [1,21,23]. Many epidemiologic studies have used these different opera-
tional definitions to investigate the association between sarcopenia and various pathologic
conditions (e.g., cardio-metabolic diseases, recurrent falling and fracture, and mortality).
However, the observed prevalence of sarcopenia using the different definitions was very
different and agreement among the three definitions was also very low [28]. Several
meta-analysis studies found significant associations between sarcopenia and NAFLD/liver
fibrosis [15,29]; however, these studies did not consider the different criteria for sarcopenia.
In 2014, Hong et al. [30] suggested a significant relationship between sarcopenia defined
by wSMI and NAFLD after adjusting for potential confounding factors. Lee et al. [31]
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reported that sarcopenia defined by wSMI is associated with increased risks of NAFLD and
advanced fibrosis, independent of obesity or metabolic syndrome using the same cohort
dataset used in our study. However, Peng’s study conducted in 2019 [16] demonstrated that
for sarcopenia defined by hSMI, its association with NAFLD is in the opposite direction to
wSMI. They first suggested that the different definitions of SMI could substantially influ-
ence study outcomes, particularly in relation to NAFLD. Peng’s study used a bio-resistance
body composition analyzer for assessing muscle mass and they conducted the study only in
participants aged 60–75 years [16]. Most recently, Kang et al. [32] examined the association
of skeletal muscle and adipose tissue distribution with biopsy-proven NAFLD. Kang’s
study defined sarcopenia by hSMI and showed a negative association between hLSMI and
hepatic steatosis.
The results of our study are consistent with previous studies suggesting that dif-
ferent sarcopenia definitions have different associations with NAFLD. In the current
study, we found a positive association between wLSMI/bLSMI and NAFLD and a neg-
ative association between hLSMI and NAFLD in adults aged 19 years and older using
sex-specific analysis.
Possible mechanisms of the interaction between sarcopenia and NAFLD are based on
effects of insulin resistance [33,34], chronic inflammation [30], and crosstalk between organs
by secretion of cytokines, such as hepatokines, adipokines, and myokines [35,36]. The
present study showed a significantly higher correlation between wSMI and both HOMA-IR
and NAFLD-liver fat score in men, whereas hSMI showed a correlation in the opposite
direction in both men and women. These results suggest that the link between sarcope-
nia and NAFLD is via insulin resistance. In addition, we compared body composition
according to the three definitions of SMI to determine the relative fat mass associated
with low muscle mass in each definition. Interestingly, appendicular fat mass, subtotal fat
mass, and percentage of subtotal fat mass were significantly higher in sarcopenia defined
by wSMI and bSMI, whereas appendicular fat mass and subtotal fat mass were lower in
sarcopenia defined by hSMI. When muscle mass was adjusted by weight and BMI, subjects
with sarcopenia may have high relative fat mass, which could be the main cause of the
association with NAFLD.
Although the reason that the predictive power of hSMI was only significantly higher
than that of bSMI, and others were not significantly different in women, is unclear, sex-
based differences in skeletal muscle fiber type, composition and function hormonal effects
might affect these discrepant results.
This study also has several limitations. First, we could not examine muscle strength
and physical performance due to lack of data in the KNHANES. Since sarcopenia is defined
as a decrease in muscle mass, muscle strength, and physical performance, further studies
are needed to confirm the predictive power for NAFLD according to muscle strength and
physical performance as well as muscle mass. Second, we used a validated non-invasive
biomarker, NAFLD-liver fat score, to assess NAFLD, rather than liver imaging or histologi-
cal information. The gold standard for diagnosis of NAFLD is liver biopsy; however, it has
disadvantages such as high cost, sampling error, and complications related to invasive pro-
cedures [37]. Finally, the causal relationship between low muscle mass and NAFLD could
not be demonstrated because of the cross-sectional study design. Further longitudinal
studies are required to find the causal relationship between sarcopenia and NAFLD.
The strength and novelty of our study is that we not only compare the predictive
power of the three definitions of SMI for NAFLD, but also demonstrate the possible
explanations for the results by showing the association with insulin resistance and the
comparison of fat mass. Second, our data assessed muscle mass using the DXA, which is a
gold standard tool for measurement of body composition, including muscle mass. Finally,
we conducted a sex-specific analysis considering the different body compositions of men
and women. Although there is still no unified definition of LSMI, our study showed the
highest diagnostic performance of wSMI for the prediction of NAFLD in men.
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5. Conclusions
The predictive power of wSMI for NAFLD is significantly higher than those of hSMI
and bSMI in men. Moreover, hSMI shows correlations with HOMA-IR and NAFLD-liver
fat score in the opposite direction to wSMI/bSMI. Consensus on the operational criteria to
clarify the association between sarcopenia and NAFLD is much needed.
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